Adjuvant and neo-adjuvant therapy
32 ASTRRA study: a randomised phase III study for evaluating the role of the addition of ovarian function suppression (OFS) to tamoxifen in young women (<45 years) with hormone-sensitive breast cancer who remain in premenopause or regain menstruation after chemotherapy – a Korean Breast Cancer Study Group (KBCSG) trial